"Bromocriptine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.
| Descriptor ID |
D001971
|
| MeSH Number(s) |
D03.132.327.412.100 D03.633.400.439.131 D03.633.400.562.100
|
| Concept/Terms |
Bromocriptine- Bromocriptine
- 2-Bromo-alpha-ergokryptine
- 2 Bromo alpha ergokryptine
- Bromocryptin
- 2-Bromoergokryptine
- 2 Bromoergokryptine
- Bromocriptin
- 2-Bromoergocryptine
- 2 Bromoergocryptine
- 2-Bromo-alpha-ergocryptine
- 2 Bromo alpha ergocryptine
2-Bromoergocryptine Mesylate- 2-Bromoergocryptine Mesylate
- 2 Bromoergocryptine Mesylate
- Mesylate, 2-Bromoergocryptine
- Bromocriptine Mesylate
- Mesylate, Bromocriptine
- 2-Bromoergocryptine Methanesulfonate
- 2 Bromoergocryptine Methanesulfonate
- Methanesulfonate, 2-Bromoergocryptine
|
Below are MeSH descriptors whose meaning is more general than "Bromocriptine".
Below are MeSH descriptors whose meaning is more specific than "Bromocriptine".
This graph shows the total number of publications written about "Bromocriptine" by people in this website by year, and whether "Bromocriptine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 2 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Bromocriptine" by people in Profiles.
-
Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins. 2021 11; 89(11):1425-1441.
-
Acute transverse myelitis with Dysautonomia following SARS-CoV-2 infection: A case report and review of literature. J Neuroimmunol. 2021 04 15; 353:577523.
-
Neuroleptic malignant syndrome in a COVID-19 patient. Brain Behav Immun. 2020 08; 88:28-29.
-
A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism. Liver Int. 2019 04; 39(4):684-693.
-
Prolactin, autoimmunity, and motherhood: when should women avoid breastfeeding? Clin Rheumatol. 2019 May; 38(5):1263-1270.
-
Reply to 'More study still needed on the use of bromocriptine in the treatment of peripartum cardiomyopathy'. Eur Heart J. 2018 11 14; 39(43):3905.
-
Reply to 'Bromocriptine for the treatment of peripartum cardiomyopathy: comparison of outcome with a nationwide Danish cohort'. Eur Heart J. 2018 10 01; 39(37):3478.
-
Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. Clin Res Cardiol. 2019 Mar; 108(3):290-297.
-
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017 Sep 14; 38(35):2671-2679.
-
Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD. Eur Heart J. 2017 09 14; 38(35):2680-2682.